A practical reference on bioavailability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-15 and is reviewed periodically as new material appears.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
2C-B has been reported to be an allosteric or non-competitive serotonin transporter (SERT) inhibitor or serotonin reuptake inhibitor, albeit of very low potency. Although 2C-B itself was not evaluated, other closely related members of the 2C series, including 2C-C, 2C-D, 2C-E, 2C-I, and 2C-T-2, all showed no activity as monoamine releasing agents of serotonin, norepinephrine, or dopamine (EC50 = >100,000 nM or "inactive"). 2C-B shows dopaminergic actions mediated by the dopamine transporter (DAT) in monkeys but not in rodents. 2C-B produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It shows reinforcing effects in monkeys but not in rodents. The drug also shows potent and efficacious anti-inflammatory effects in preclinical research. In contrast to MDMA, which robustly increases oxytocin levels and produces associated entactogenic effects, 2C-B minimally affects oxytocin levels in humans.
== Further reading == Markwell, John; Brooks, David W. (2002). "Broken Links: The Ephemeral Nature of Educational WWW Hyperlinks". Journal of Science Education and Technology. 11 (2): 105–108. Bibcode:2002JSEdT..11..105M. doi:10.1023/A:1014627511641. Gomes, Daniel; Silva, Mário J. (2006). "Modelling Information Persistence on the Web" (PDF). Proceedings of the 6th International Conference on Web Engineering. ICWE'06. Archived from the original (PDF) on 2011-07-16. Retrieved 14 September 2010. Dellavalle, Robert P.; Hester, Eric J.; Heilig, Lauren F.; Drake, Amanda L.; Kuntzman, Jeff W.; Graber, Marla; Schilling, Lisa M. (31 October 2003). "Going, Going, Gone: Lost Internet References". Science. 302 (5646): 787–788. doi:10.1126/science.1088234. PMID 14593153. Koehler, Wallace (1999). "An Analysis of Web Page and Web Site Constancy and Permanence". Journal of the American Society for Information Science. 50 (2): 162–180. doi:10.1002/(SICI)1097-4571(1999)50:2<162::AID-ASI7>3.0.CO;2-B. Sellitto, Carmine (2005). "The impact of impermanent Web-located citations: A study of 123 scholarly conference publications" (PDF). Journal of the American Society for Information Science and Technology. 56 (7): 695–703. doi:10.1002/asi.20159.
In chemical reactors, the goal is to make components react with a high yield. In a homogeneous, first-order reaction, the probability that an atom or molecule will react depends only on its residence time:
=== Nonsense === Nonsense mutations are changes in DNA sequence that introduce a premature stop codon, causing any resulting protein to be abnormally shortened. This often causes a loss of function in the protein, as critical parts of the amino acid chain are no longer assembled. Because of this terminology, stop codons have also been referred to as nonsense codons.
Heseltine was disappointed not to receive the support of old allies on the second ballot; these included Secretary of State for Defence Tom King (whom he asked in vain to second his nomination, but who was angry at a leadership contest when British troops were soon to go to war in Kuwait and supported Douglas Hurd), Cecil Parkinson and Norman Lamont (who managed John Major's campaign). Over the weekend on 24–25 November, many Conservative MPs were faced with the anger of their local party members who overwhelmingly supported Thatcher but did not at that time have a vote in leadership elections, and opinion polls showed that chancellor John Major would also boost Conservative support if leader (previously Heseltine's unique selling-point). Heseltine had never done much to court support among younger MPs the way Major had, and was seen as aloof even by his own supporters. In the second ballot, a week after the first, Heseltine's vote actually fell to 131 (just over 35%) as some MPs had voted for him in the first ballot as a protest against or to try to oust Thatcher but preferred to vote for other candidates now that they had a wider choice. John Major, with 185 votes, was only two votes short of an overall majority. Heseltine immediately and publicly conceded defeat, announcing that he would vote for Major if the third ballot went ahead (it did not, as Hurd, who had finished a distant third, also conceded).
Sources: en.wikipedia.org
==== Metabolism ==== Gepirone is metabolized primarily by CYP3A4. Its major metabolites are 1-PP and 3'-OH-gepirone, both of which are pharmacologically active. These metabolites are present in the circulation at higher concentrations than gepirone.
== History == The first Canadian A&W restaurant opened in Winnipeg, Manitoba, in 1956. It spread across Canada with over 200 locations in the next ten years. The Canadian restaurants were part of the American chain until 1972 when they were sold to Unilever. In 1975, facing competition from the growing Canadian operations of McDonald's, the company launched an advertising campaign starring an orange-clad mascot, The Great Root Bear. The bear and the tuba jingle that accompanied him became a long-running campaign (the tune, entitled "Ba-Dum, Ba-Dum", was released as a single by Attic Records, credited to "Major Ursus", a play on Ursa Major or "great bear"). The famous Canadian composer and B.C. Hall of Fame winner Robert Buckley helped compose the song. The mascot was so successful that he was eventually adopted as the mascot by the American A&W chain as well. The famous tuba jingle was played by famed Vancouver jazz, classical and session trombonist Sharman King. In the early 1980s, the drive-in style of restaurant was phased out. It was replaced with a modern, pastel-coloured fast food outlet which included marginally healthier options. While the chain continued to open some standalone restaurants, A&W also aggressively pursued shopping mall locations, and as a result A&Ws are still commonly found in Canadian malls of various sizes.
== Applications == Synthetic antibodies have shown their utility in a number of applications. Their use within the field of research lies predominantly in the life sciences as reagents for protein capture and as protein inhibitors. Within diagnostics they have been utilised in applications ranging from infection and cancer screening to mycotoxin detection in grain samples. Synthetic antibodies are currently the fastest growing class of therapeutics.
=== Welfare of unorganized workers === The Labour Department under Lad has also pursued measures aimed at extending social-security coverage to workers outside conventional organized employment. In 2024, the state introduced the Ambedkar Karmikara Sahaya Hasta Yojane for additional categories of unorganized workers, with benefits including insurance and other forms of assistance. In 2025, Lad proposed a ₹1-per-litre fuel cess to create a dedicated healthcare fund for unorganized workers. He said such a mechanism could generate substantial resources for worker healthcare and support a proposed health-card system.
Sources: en.wikipedia.org
==== 3.A. P-P-bond hydrolysis-driven transporters ==== 3.A.1 ABC transporters including BtuCD, molybdate uptake transporter, Cystic fibrosis transmembrane conductance regulator and others 3.A.2 The H+- or Na+-translocating F-type ATPase, V-type ATPase and A-type ATPase superfamily 3.A.3 The P-type ATPase Superfamily 3.A.4 The Arsenite-Antimonite efflux family 3.A.5 General secretory pathway (Sec) translocon (preprotein translocase SecY) 3.A.6 The Type III (Virulence-related) Secretory Pathway (IIISP) Family 3.A.7 The Type IV (Conjugal DNA-Protein Transfer or VirB) Secretory Pathway (IVSP) Family 3.A.8 The Mitochondrial Protein Translocase (MPT) Family 3.A.9 The Chloroplast Envelope Protein Translocase (CEPT or Tic-Toc) Family 3.A.10 H+, Na+-translocating Pyrophosphatase family 3.A.11 The Bacterial Competence-related DNA Transformation Transporter (DNA-T) Family 3.A.12 The Septal DNA Translocator (S-DNA-T) Family 3.A.13 The Filamentous Phage Exporter (FPhE) Family 3.A.14 The Fimbrilin/Protein Exporter (FPE) Family 3.A.15 The Outer Membrane Protein Secreting Main Terminal Branch (MTB) Family 3.A.16 The Endoplasmic Reticular Retrotranslocon (ER-RT) Family 3.A.17 The Phage T7 Injectisome (T7 Injectisome) Family 3.A.18 The Nuclear mRNA Exporter (mRNA-E) Family 3.A.19 The TMS Recognition/Insertion Complex (TRC) Family 3.A.20 The Peroxisomal Protein Importer (PPI) Family 3.A.21 The C-terminal Tail-Anchored Membrane Protein Biogenesis/ Insertion Complex (TAMP-B) Family 3.A.22 The Transcription-coupled TREX/TAP Nuclear mRNA Export Complex (TREX) Family 3.A.23 The Type VI Symbiosis/Virulence Secretory Pathway (VISP) Family 3.A.24 Type VII or ESX Protein Secretion System (T7SS) Family 3.A.25 The Symbiont-specific ERAD-like Machinery (SELMA) Family 3.A.26 The Plasmodium Translocon of Exported proteins (PTEX) Family
Rui Pedro Teixeira Mendonça (born 28 January 1987) is a Portuguese boy who went missing on 4 March 1998 in Lousada, northern Portugal. Mendonça was 11 years old and riding his bicycle outside near his home when he disappeared. The subsequent police investigation was criticized by both the media and by the missing boy's family. Mendonça's whereabouts remain unknown, and he was declared legally dead in 2019.
Antibacterials are used to treat bacterial infections. Antibiotics are classified generally as beta-lactams, macrolides, quinolones, tetracyclines or aminoglycosides. Their classification within these categories depends on their antimicrobial spectra, pharmacodynamics and chemical composition. Prolonged use of certain antibacterials can decrease the number of enteric bacteria, which may have a negative impact on health. Consumption of probiotics and healthy eating may help to replace destroyed gut flora. Stool transplants may be considered however for patients who are having difficulty recovering from prolonged antibiotic treatment, such as recurrent Clostridioides difficile infections. The discovery, development and use of antibacterials during the 20th century have reduced mortality from bacterial infections. The antibiotic era began with the therapeutic application of sulfonamide drugs in 1936, followed by a "golden" period of discovery from about 1945 to 1970, when a number of structurally diverse and highly effective agents were discovered and developed. Since 1980, the introduction of new antimicrobial agents for clinical use has declined, in part because of the enormous expense of developing and testing new drugs. In parallel, there has been an alarming increase in antimicrobial resistance of bacteria, fungi, parasites and some viruses to multiple existing agents. Antibacterials are among the most commonly used and misused drugs by physicians, for example, in viral respiratory tract infections.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.